Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Cash & Equivalents (2019 - 2025)

Pulmonx (LUNG) has disclosed Cash & Equivalents for 6 consecutive years, with $70.9 million as the latest value for Q4 2024.

  • On a quarterly basis, Cash & Equivalents fell 15.13% to $70.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was $70.9 million, a 15.13% decrease, with the full-year FY2024 number at $70.9 million, down 15.13% from a year prior.
  • Cash & Equivalents was $70.9 million for Q4 2024 at Pulmonx, up from $63.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $231.6 million in Q4 2020 to a low of $16.2 million in Q1 2020.
  • A 5-year average of $110.0 million and a median of $101.7 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 1468.1% in 2020, then plummeted 40.24% in 2022.
  • Pulmonx's Cash & Equivalents stood at $231.6 million in 2020, then crashed by 35.88% to $148.5 million in 2021, then plummeted by 31.48% to $101.7 million in 2022, then dropped by 17.88% to $83.5 million in 2023, then fell by 15.13% to $70.9 million in 2024.
  • Per Business Quant, the three most recent readings for LUNG's Cash & Equivalents are $70.9 million (Q4 2024), $63.3 million (Q3 2024), and $63.5 million (Q2 2024).